Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Stüve O[au]:

Removal Notice. et al. Mult Scler. (2017)

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. Nash RA et al. Neurology. (2017)

Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis. Shirani A et al. Neurotherapeutics. (2016)

Search results

Items: 1 to 50 of 250

1.

Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.

Berger T, Stüve O.

Neurology. 2019 Feb 8. pii: 10.1212/WNL.0000000000007022. doi: 10.1212/WNL.0000000000007022. [Epub ahead of print] No abstract available.

PMID:
30737335
2.

Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.

Arendt G, Schlonies S, Orhan E, Stüve O.

J Neurovirol. 2019 Jan 9. doi: 10.1007/s13365-018-0701-x. [Epub ahead of print]

PMID:
30628025
3.

TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency.

Hussain RZ, Cravens PC, Doelger R, Dentel B, Herndon E, Loof N, Tsai P, Okuda DT, Racke MK, Stüve O.

Ann Clin Transl Neurol. 2018 Oct 30;5(12):1543-1561. doi: 10.1002/acn3.664. eCollection 2018 Dec.

4.

PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome.

Dubey D, Hussain RZ, Miller-Little WA, Salter A, Doelger R, Stüve O.

J Neuroimmunol. 2018 Oct 15;323:53-55. doi: 10.1016/j.jneuroim.2018.07.012. Epub 2018 Jul 25.

PMID:
30196834
5.

Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.

Cummings M, Arumanayagam ACS, Zhao P, Kannanganat S, Stuve O, Karandikar NJ, Eagar TN.

PLoS One. 2018 Aug 8;13(8):e0200752. doi: 10.1371/journal.pone.0200752. eCollection 2018.

6.

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE.

Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.

PMID:
29908077
7.

Emerging drugs for primary progressive multiple sclerosis.

Narayan RN, Forsthuber T, Stüve O.

Expert Opin Emerg Drugs. 2018 Jun;23(2):97-110. doi: 10.1080/14728214.2018.1463370. Epub 2018 Apr 24. Review.

PMID:
29638150
8.

B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets.

Forsthuber TG, Cimbora DM, Ratchford JN, Katz E, Stüve O.

Ther Adv Neurol Disord. 2018 Mar 21;11:1756286418761697. doi: 10.1177/1756286418761697. eCollection 2018. Review.

9.

Similar Biophysical Abnormalities in Glomeruli and Podocytes from Two Distinct Models.

Embry AE, Liu Z, Henderson JM, Byfield FJ, Liu L, Yoon J, Wu Z, Cruz K, Moradi S, Gillombardo CB, Hussain RZ, Doelger R, Stuve O, Chang AN, Janmey PA, Bruggeman LA, Miller RT.

J Am Soc Nephrol. 2018 May;29(5):1501-1512. doi: 10.1681/ASN.2017050475. Epub 2018 Mar 23.

PMID:
29572404
10.

Natalizumab: Perspectives from the Bench to Bedside.

Shirani A, Stüve O.

Cold Spring Harb Perspect Med. 2018 Dec 3;8(12). pii: a029066. doi: 10.1101/cshperspect.a029066. Review.

PMID:
29500304
11.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

12.

B-cell-targeted therapies in relapsing forms of MS.

Dubey D, Forsthuber T, Flanagan EP, Pittock SJ, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e405. doi: 10.1212/NXI.0000000000000405. eCollection 2017 Nov. Review.

13.

Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.

D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O.

J Crohns Colitis. 2018 Jan 24;12(2):188-196. doi: 10.1093/ecco-jcc/jjx128.

14.

Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post-lumbar puncture headache.

Stüve O, Cataldi F, Pradhan V, Gorelick KJ.

J Neuroimmunol. 2017 Sep 15;310:69-71. doi: 10.1016/j.jneuroim.2017.06.011. Epub 2017 Jun 30.

15.

Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.

PMID:
28601278
16.

Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.

Shirani A, Stüve O.

J Immunol. 2017 Feb 15;198(4):1381-1386. doi: 10.4049/jimmunol.1601358. Review.

17.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

18.

The major histocompatibility complex and antibody-mediated limbic encephalitis.

Stüve O, Vernino S.

Ann Neurol. 2017 Feb;81(2):181-182. doi: 10.1002/ana.24861. No abstract available.

PMID:
28026032
19.

Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project.

Dickerson E, Davenport MS, Syed F, Stuve O, Cohen JA, Rinker JR, Goldman MD, Segal BM, Foerster BR; Michigan Radiology Quality Collaborative.

J Am Coll Radiol. 2017 Mar;14(3):371-379.e1. doi: 10.1016/j.jacr.2016.09.037. Epub 2016 Dec 5.

PMID:
27932248
20.

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis.

Milo R, Stüve O.

Degener Neurol Neuromuscul Dis. 2016 Nov 17;6:95-109. doi: 10.2147/DNND.S85747. eCollection 2016. Review.

21.

IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation.

Cravens PD, Hussain RZ, Miller-Little WA, Ben LH, Segal BM, Herndon E, Stüve O.

PLoS One. 2016 Oct 25;11(10):e0165248. doi: 10.1371/journal.pone.0165248. eCollection 2016.

22.

Targeting "bad" B cells in multiple sclerosis: Could laquinimod be part of the armamentarium?

Forsthuber TG, Stuve O.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 21;3(5):e283. eCollection 2016 Oct. No abstract available.

23.

Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis.

Menge T, Dubey D, Warnke C, Hartung HP, Stüve O.

Expert Rev Neurother. 2016 Oct;16(10):1131-9. doi: 10.1080/14737175.2016.1227242. Epub 2016 Sep 1. Review.

PMID:
27552111
24.

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.

Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, Hemmer B, Rieckmann P, Montalban X, Ziemssen T, Hunter B, Arnould S, Wallström E, Selmaj K.

JAMA Neurol. 2016 Sep 1;73(9):1089-98. doi: 10.1001/jamaneurol.2016.1451.

PMID:
27380540
25.

Diagnostic and therapeutic strategies for management of autoimmune encephalopathies.

Dubey D, Blackburn K, Greenberg B, Stuve O, Vernino S.

Expert Rev Neurother. 2016 Aug;16(8):937-49. doi: 10.1080/14737175.2016.1189328. Epub 2016 May 30. Review.

PMID:
27171736
26.

Managing Disability in Progressive Multiple Sclerosis.

Dubey D, Sguigna P, Stüve O.

Curr Treat Options Neurol. 2016 Jun;18(6):27. doi: 10.1007/s11940-016-0412-7. Review.

PMID:
27089873
27.

Tumefactive demyelination following herbal supplement use: Cause or coincidence?

Dubey D, Golden E, Suss A, Cano CA, Krishnan G, Stuve O.

J Postgrad Med. 2016 Apr-Jun;62(2):136-7. doi: 10.4103/0022-3859.180577. No abstract available.

28.

In Memoriam: John F. Kurtzke, MD (1926-2015): A Founding Father of Neuroepidemiology and Pioneer of Modern Clinical Trial Design.

Frohman EM, Stüve O, Frohman TC, Lisak R.

JAMA Neurol. 2016 Apr;73(4):482-3. doi: 10.1001/jamaneurol.2016.0030. No abstract available.

PMID:
27064556
29.

Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of 'Chinese restaurant syndrome'.

Leussink VI, Hartung HP, Stüve O, Kieseier BC.

J Neurol. 2016 May;263(5):1027-1028. doi: 10.1007/s00415-016-8110-7. Epub 2016 Apr 8. No abstract available.

PMID:
27060083
30.

A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR.

Arellano B, Hussain R, Miller-Little WA, Herndon E, Lambracht-Washington D, Eagar TN, Lewis R, Healey D, Vernino S, Greenberg BM, Stüve O.

PLoS One. 2016 Apr 7;11(4):e0152720. doi: 10.1371/journal.pone.0152720. eCollection 2016.

31.

Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis.

Dubey D, Cano CA, Stüve O.

Curr Opin Neurol. 2016 Jun;29(3):272-7. doi: 10.1097/WCO.0000000000000320. Review.

PMID:
27035896
32.

Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis.

Dubey D, Cano CA, Stüve O.

Curr Opin Neurol. 2016 Jun;29(3):278-85. doi: 10.1097/WCO.0000000000000321. Review.

PMID:
27027553
33.

Will Biomarkers Determine What Is Next in Multiple Sclerosis?: Biomarkers in Multiple Sclerosis.

Stüve O, Racke MK.

JAMA Neurol. 2016 May 1;73(5):496-7. doi: 10.1001/jamaneurol.2015.4841. No abstract available.

PMID:
26954286
34.

Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.

Hussain R, O'Leary S, Pacheco FM, Zacharias TE, Litvak P, Sguigna P, Marder E, Kia K, Kooner K, Stüve O.

J Neurol. 2016 Mar;263(3):606-10. doi: 10.1007/s00415-015-7999-6. Epub 2016 Feb 25.

PMID:
26914924
35.

Primary progressive multiple sclerosis--why we are failing.

Segal BM, Stüve O.

Lancet. 2016 Mar 12;387(10023):1032-1034. doi: 10.1016/S0140-6736(16)00158-6. Epub 2016 Jan 28. No abstract available.

PMID:
26827076
36.

B cell-directed therapies in multiple sclerosis.

Gasperi C, Stüve O, Hemmer B.

Neurodegener Dis Manag. 2016;6(1):37-47. doi: 10.2217/nmt.15.67. Review.

PMID:
26782316
37.

Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.

Shirani A, Okuda DT, Stüve O.

Neurotherapeutics. 2016 Jan;13(1):58-69. doi: 10.1007/s13311-015-0409-z. Review.

38.

The spectrum of autoimmune encephalopathies.

Dubey D, Sawhney A, Greenberg B, Lowden A, Warnack W, Khemani P, Stuve O, Vernino S.

J Neuroimmunol. 2015 Oct 15;287:93-7. doi: 10.1016/j.jneuroim.2015.08.014. Epub 2015 Aug 28.

PMID:
26439968
39.

Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab.

Dubey D, Cano CA, Stuve O.

Neuropsychiatr Dis Treat. 2015 Sep 18;11:2405-14. doi: 10.2147/NDT.S90473. eCollection 2015. Review.

40.

Smoking Beyond Multiple Sclerosis Diagnosis: A Risk Factor Still Worth Modifying.

Goldman MD, Stüve O.

JAMA Neurol. 2015 Oct;72(10):1105-6. doi: 10.1001/jamaneurol.2015.1805. No abstract available.

PMID:
26348489
41.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

42.

In Memoriam: Jean Lindenmann (1924-2015): A Circuitous Interfering Power in Neurology.

Stüve O.

JAMA Neurol. 2015 Jun;72(6):728-9. doi: 10.1001/jamaneurol.2015.0439. No abstract available.

PMID:
26053448
43.

Natalizumab to fingolimod: Questions answered, unanswered, and unasked.

Stüve O, Bourdette D.

Neurology. 2015 Jul 7;85(1):14-5. doi: 10.1212/WNL.0000000000001722. Epub 2015 May 29. No abstract available.

PMID:
26024898
44.

Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.

Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, Klawiter EC, Tenembaum SN, Banwell B, Greenberg BM, Bennett JL, Levy M, Villoslada P, Saiz A, Fujihara K, Chan KH, Schippling S, Paul F, Kim HJ, de Seze J, Wuerfel JT; Guthy-Jackson Charitable Foundation (GJCF) Neuromyelitis Optica (NMO) International Clinical Consortium and Biorepository, Cabre P, Marignier R, Tedder T, van Pelt D, Broadley S, Chitnis T, Wingerchuk D, Pandit L, Leite MI, Apiwattanakul M, Kleiter I, Prayoonwiwat N, Han M, Hellwig K, van Herle K, John G, Hooper DC, Nakashima I, Sato D, Yeaman MR, Waubant E, Zamvil S, Stüve O, Aktas O, Smith TJ, Jacob A, O'Connor K.

JAMA Neurol. 2015 Jul;72(7):815-22. doi: 10.1001/jamaneurol.2015.0248. Review.

45.

B lymphocytes in neuromyelitis optica.

Bennett JL, O'Connor KC, Bar-Or A, Zamvil SS, Hemmer B, Tedder TF, von Büdingen HC, Stuve O, Yeaman MR, Smith TJ, Stadelmann C.

Neurol Neuroimmunol Neuroinflamm. 2015 May 7;2(3):e104. doi: 10.1212/NXI.0000000000000104. eCollection 2015 Jun. Review.

46.

Spinal gout: A rare cause of paraplegia.

Dubey D, Steen E, Sawhney A, Stuve O.

Neurol India. 2015 Mar-Apr;63(2):284-5. doi: 10.4103/0028-3886.156318. No abstract available.

47.

Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis--an observational study.

Rommer PS, Buckow K, Ellenberger D, Friede T, Pitschnau-Michel D, Fuge J, Stüve O, Zettl UK; German Multiple Sclerosis Registry of the German National MS Society.

Eur J Clin Invest. 2015 Jun;45(6):587-93. doi: 10.1111/eci.12450. Epub 2015 May 9.

PMID:
25868705
48.

Multiple sclerosis drugs: how much bang for the buck?

Stüve O, Cutter GR.

Lancet Neurol. 2015 May;14(5):460-1. doi: 10.1016/S1474-4422(15)00016-2. Epub 2015 Apr 1. No abstract available.

PMID:
25841666
49.

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O.

Expert Rev Neurother. 2015 Apr;15(4):339-46. doi: 10.1586/14737175.2015.1025755. Review.

PMID:
25800129
50.

Treatment decisions for patients with active multiple sclerosis.

Stüve O, Centonze D.

JAMA Neurol. 2015 Apr;72(4):387-9. doi: 10.1001/jamaneurol.2014.4494. No abstract available.

PMID:
25664937

Supplemental Content

Support Center